{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["CT-202"]],"indication":"recurring triple negative breast, colorectal and urothelial cancers","name":"NCT07545122","nct_id":"NCT07545122","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct07545122. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CT-202","arms":[{"description":"Dose Escalation-Bayesian Optimal Interval (BOIN) Design with approximately 54 patients in dose escalation.","label":"Phase 1a","type":"EXPERIMENTAL"},{"description":"Phase 1b: Dose Expansion - participants will be evaluated in 4-6 cohorts at different doses and schedules of CT-202","label":"Phase 1b","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-01","type":"ESTIMATED"},"conditions":["Triple Negative Breast Cancer (TNBC)","Colorectal Cancer","Urothelial Cancer"],"enrollment":{"count":162,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"CT-202","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-16","lead_sponsor":"Context Therapeutics Inc.","official_title":"A Phase 1a/1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, and Urothelial Cancers","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2030-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1a: Incidence of Dose Limiting Toxicities (DLTs)","timeFrame":"From date of first dose of CT-202 until 28 days following the first dose"},{"measure":"Phase 1b: Overall response rate (ORR)","timeFrame":"From date of first dose of CT-202until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months"}],"references":[],"start_date":{"date":"2026-09-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers","url":"https://clinicaltrials.gov/study/NCT07545122"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct07545122"}